Ac0058, a new class 1.1 drug of Eisen medicine, has been approved by FDA

Hangzhou Essen Pharmaceutical Research Co., Ltd (hereinafter referred to as "Essen pharmaceutical") independently developed the national class 1.1 innovative drug ac0058, which was recently approved by the US FDA and will carry out phase I clinical research in the US The innovative drug is one of the achievements of the 12th Five Year Plan of the national science and technology major project of "major new drug creation" Ac0058, developed by Hangzhou Essen Pharmaceutical Research Co., Ltd., is a new mechanism small molecule compound, which is used to treat autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis by specifically inhibiting the key regulatory molecule of B-lymphocytes and other inflammatory cells The juxtaposition of autoimmune diseases and tumors is one of the two hot spots and difficulties in medical research Due to the complex diversity of autoimmune diseases and the characteristics of long course of disease, higher requirements are put forward in drug efficacy and safety Ac0058, as an oral small molecule drug, has shown good therapeutic effect and safety in preclinical research, which is expected to change the previous expensive situation of injection in this field and become a valuable alternative for the treatment of autoimmune diseases Founded in October 2003, Essen Biosciences (Hangzhou) Co., Ltd is wholly owned by ACEA Biosciences Inc and is headquartered in the Silicon Valley of biology, San Diego, California Eisen biological (Hangzhou) Co., Ltd is a high-tech company integrating production, R & D, sales and technical support It is committed to developing a series of products with international advanced level, such as automatic biological cell analysis system Its core technology and product, real-time cell analysis system, has won the National Technological Innovation Award for small and medium-sized scientific and technological enterprises At present, the company has mastered international advanced technologies such as microelectronic biocell sensor chip preparation, biological signal to electronic signal conversion, data acquisition and analysis, supporting analysis software design, and has independent intellectual property rights, which is in the leading position in the international biochip technology competition   ​